概述
The Extended GH Stack adds IGF-1 LR3 to the classic CJC-1295 + Ipamorelin base, creating a three-tier growth hormone axis protocol that addresses GH secretion, GH release, and downstream IGF-1 signaling simultaneously. CJC-1295 and Ipamorelin handle the upstream signaling — increasing GH output through GHRH and ghrelin pathways respectively. IGF-1 LR3 (a long-acting analog of Insulin-like Growth Factor-1) enters downstream, acting directly on muscle, bone, and organ cells to drive protein synthesis, cellular hypertrophy, and tissue growth — the actual anabolic outcomes that elevated GH is designed to produce. The practical advantage of adding IGF-1 LR3 is ensuring the anabolic signal reaches peripheral tissue even when natural liver conversion of GH to IGF-1 is suboptimal — common with age, metabolic dysfunction, or intensive training loads. IGF-1 LR3 has a 20–30 hour half-life compared to native IGF-1''s minutes, providing sustained receptor activation throughout the day. This stack is for experienced users who have established a response to the classic GH stack and want to extend its downstream effects. IGF-1 LR3 is administered post-workout to direct its anabolic action toward recently trained muscle tissue. This protocol requires blood work monitoring of IGF-1 levels (often quarterly), fasting glucose, and HbA1c due to IGF-1''s insulin-like effects on glucose metabolism.
给药方案
300 mcg
每剂
300 mcg
每剂
50 mcg
每剂
目标与证据
警告
- IGF-1 LR3 carries significant risk if IGF-1 levels are not monitored. Contraindicated with any cancer history. Requires medical supervision.
Comments
Sign in to join the discussion
免责声明: 此堆栈由社区提交,仅供研究用途。Peptide Contacts不对提交的堆栈的安全性或有效性进行验证。使用任何肽类协议前,请务必咨询合格的医疗专业人员。